Physician profile
Rupinder Chatha
NPI 1700856648
$4,628.17
in general payments reported to CMS, 2019-2025
32 companies · $1,224 in 2025
The $1,224 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $423 · 2021: $343 · 2022: $694 · 2023: $793 · 2024: $714 · 2025: $1,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,730.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $898.16 | 2022-2025 | |
| Vifor Pharma, INC. | $656.76 | 2019-2025 | Veltassa |
| Astrazeneca Pharmaceuticals Lp | $540.16 | 2020-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $340.78 | 2019-2023 | Krystexxa |
| Travere Therapeutics, INC. | $290.56 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $273.22 | 2021-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $214.62 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $201.63 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $186.96 | 2020-2023 | Acthar |
| Amgen INC. | $160.14 | 2019-2025 | Tavneos |
| Baxter Healthcare | $118.48 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.91 | 2020-2023 | Gattex |
| Glaxosmithkline, LLC. | $85.04 | 2020-2023 | Benlysta |
| Aurinia Pharma U.S., INC. | $63.05 | 2023-2024 | Lupkynis |
| Genzyme Corporation | $62.47 | 2023-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $59.56 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $49.93 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $48.60 | 2025 | Jynarque |
| Novo Nordisk INC | $43.53 | 2024 | Rivfloza |
| Abbott Laboratories | $35.29 | 2024-2025 | Cardiomems |
| Ani Pharmaceuticals, INC. | $33.40 | 2025 | Purified Cortrophin Gel |
| Exact Sciences Corporation | $30.31 | 2025 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $25.35 | 2024 | Ultomiris |
| Apellis Pharmaceuticals, INC. | $24.67 | 2025 | Empaveli |
| Silk Road Medical, INC. | $21.92 | 2019 | |
| Mallinckrodt Enterprises LLC | $19.66 | 2019 | |
| Shire North American Group INC | $18.74 | 2019 | |
| Ardelyx, INC. | $18.62 | 2023 | Ibsrela |
| Akebia Therapeutics INC | $16.65 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupinder Chatha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.